7 Facts About Reports That South Korean Scientists Turned Cancer Cells Into Healthy Cells

Can Cancer Be "Tamed"?

Conventional cancer treatments generally focus on destroying tumor cells. Although chemotherapy, radiotherapy, and immunotherapy prolong life for many patients, they can cause serious adverse effects, including fatigue, immune suppression, organ damage, and impaired quality of life. Some cancers can also develop resistance to these treatments over time.

A new approach has emerged at this point: Converting cancer cells into healthy cells instead of destroying them. In other words, "educating" cancer cells or "reminding" them rather than "killing" them. This is called cancer reversion .

In January 2025, researchers at KAIST in South Korea published a study on converting colon cancer cells into healthy intestinal cells in Advanced Science . This article examines the scientific facts behind this exciting development and the extent to which the study represents a turning point.

1. Can Cancer Cells Be Turned Into Healthy Cells?

Yes, under certain genetic conditions. The KAIST study showed that cancer reversion is not merely theoretical but can be achieved in the laboratory. By suppressing MYB, HDAC2 and FOXA2 , three master regulatory genes in colon cancer cells, the researchers observed a shift toward a phenotype resembling healthy intestinal cells called enterocytes .

The genes were suppressed using both RNA-level silencing techniques (siRNA, shRNA) and epigenetic transcriptional repression (CRISPRi) .

This transformation not only halted uncontrolled growth but also normalized cellular structures and gene expression.

2. Is This a New Idea? No, but the KAIST Study Takes It Further

Similar transformation strategies had been attempted before:

• 2015, Dow et al. (Cell): Restoring the APC gene in colorectal cancer caused tumor regression and a return to a healthy cellular phenotype.

• 2019, Ishay-Ronen et al. (Cancer Cell): Breast cancer cells were converted into fat cells using a combination of a MEK inhibitor and rosiglitazone.

• 2025, KAIST (Advanced Science): Genetic programming returned colon cancer cells to intestinal epithelial cells, their tissue of origin.

What distinguishes the KAIST study is that the transformation was computationally modeled, experimentally validated, and supported by tumor shrinkage in living mouse models.

3. How Does Cell Conversion Occur?

Using 4,252 human colon cells, the researchers developed BENEIN (Boolean Network Inference and Control), a computational model. It analyzed approximately 2,000 interactions among 522 genes to map the "attractor states" that determine cell fate.

The simulations predicted that suppressing MYB, HDAC2 and FOXA2 could move cells from a malignant to a healthy state. These predictions were confirmed in the laboratory. Cells with the genes suppressed began behaving more like enterocytes than aggressive tumor cells.

Tests in mouse models showed that cells reprogrammed in this way had a substantially reduced capacity to form tumors.

4. Could This Approach Work in Other Cancers?

The initial test involved colon cancer, but similar epigenetic and genetic mechanisms may exist in other cancers. Researchers believe the approach might also apply to breast, pancreatic, or hematological cancers.

However, because each cancer has its own genetic architecture, the genes required for conversion may differ by cancer type.

5. What Are the Potential Benefits and Risks?

Potential benefits:

• It may be less toxic because it treats cells without killing them.

• It may avoid damaging the immune system.

• It may reduce the development of resistance.

• Adverse effects may be minimal.

Risks:

• Not all cells may convert completely, creating a risk of new tumor formation.

• Whether the cells will remain stable over the long term is unknown.

• Because it has not yet been tested in humans, unknown safety risks may exist.

6. How Close Are We to Clinical Use?

So far, this approach has been tested only in the laboratory and in animal models . Clinical use would require:

• Phase 1 safety studies,

• Phase 2 efficacy testing,

• Phase 3 comparative clinical trials,

• And the development of optimal gene-silencing technologies.

Although some gene-silencing approaches, including RNAi, antisense oligonucleotides, and CRISPRi, are already entering use, safe, effective, tumor-specific delivery systems are needed specifically for MYB, HDAC2 and FOXA2.

7. Is a New Era in Cancer Treatment Beginning?

This study could be an important step from a paradigm of "killing cancer" toward one of "educating cancer" . Even if it does not replace conventional treatments, it could serve a complementary role as a gentler, more personalized approach.

It may also offer hope for older patients or those unable to tolerate conventional treatments. In the future, patients might receive "reprogramming cocktails" tailored to their tumor's genetic profile.

Conclusion:

Cancer reversion is moving beyond science fiction. Understanding gene-regulatory mechanisms may make it possible to restore a healthy cellular identity. The KAIST study provides some of the first preclinical evidence. The field is still at an early stage, but its direction may be promising: Smarter, gentler, and more humane cancer treatment.

Science continues to surprise us.